Acadia Pharmaceuticals (ACAD) PT Raised to $34 at JPMorgan
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $29.01 +2.73%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
JPMorgan analyst Tessa Romero raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $34.00 (from $30.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
- Genesis Minerals Ltd (GMD:AU) PT Lowered to AUD8.60 at Citi
- Evolution Mining Ltd. (EVN:AU) (CAHPF) PT Lowered to AUD13.70 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
